Diana Canetti

Sep 18, 2023 | dovepress.com | Diana Canetti |Laura Galli |Riccardo Lolatto |Silvia Nozza

Introduction A fixed combination of bictegravir/emtricitabine/tenofovir alafenamide (BFTAF, Biktarvy®), an HIV integrase strand transfer inhibitor (InSTI) associated with two nucleoside reverse transcriptase inhibitors, has been available in Italy since June 2019 for the treatment of people living with HIV infection (PLWH).1 It represents a complete single-tablet antiretroviral therapy (ART) to be taken every 24 hr, both with food and on an empty stomach, which presents very few drug...